ScoreWhy is Kiniksa Pharmaceuticals International Plc ?
1
With a growth in Operating Profit of 18.53%, the company declared Outstanding results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD 102.86 MM
- ROCE(HY) Highest at 7.39%
- DEBT-EQUITY RATIO (HY) Lowest at -63.95 %
2
With ROE of 0.97%, it has a attractive valuation with a 5.84 Price to Book Value
- Over the past year, while the stock has generated a return of 136.71%, its profits have risen by 146.8%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 136.71% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Kiniksa Pharmaceuticals International Plc should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
259.32%
EBIT Growth (5y)
17.90%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
603
Industry P/E
Price to Book Value
5.84
EV to EBIT
577.47
EV to EBITDA
432.36
EV to Capital Employed
13.62
EV to Sales
4.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.36%
ROE (Latest)
0.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend43What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 102.86 MM
ROCE(HY)
Highest at 7.39%
DEBT-EQUITY RATIO
(HY)
Lowest at -63.95 %
NET SALES(Q)
Highest at USD 180.85 MM
NET PROFIT(Q)
Highest at USD 18.43 MM
CASH AND EQV(HY)
Highest at USD 659.88 MM
OPERATING PROFIT(Q)
Highest at USD 24.41 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.49 %
PRE-TAX PROFIT(Q)
Highest at USD 27.16 MM
EPS(Q)
Highest at USD 0.23
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 15.61 times
Here's what is working for Kiniksa Pharmaceuticals International Plc
Pre-Tax Profit
At USD 27.16 MM has Grown at 661.66%
over average net sales of the previous four periods of USD 3.57 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 18.43 MM has Grown at 1,439.46%
over average net sales of the previous four periods of USD 1.2 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 102.86 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 180.85 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 180.85 MM has Grown at 36.67%
over average net sales of the previous four periods of USD 132.33 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Highest at USD 18.43 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -63.95 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Profit
Highest at USD 24.41 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 13.49 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 27.16 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
EPS
Highest at USD 0.23
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 659.88 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Kiniksa Pharmaceuticals International Plc
Debtors Turnover Ratio
Lowest at 15.61 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
